GW Pharmaceuticals

GW is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, EPIDIOLEX (cannabidiol) oral solution, is commercialized in the U.S. by its U.S. subsidiary Greenwich Biosciences for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, or tuberous sclerosis complex (TSC) in patients one year of age and older. This product has received approval in the European Union under the tradename EPIDYOLEX for the adjunctive treatment of seizures associated with LGS or Dravet syndrome in conjunction with clobazam in patients two years and older and is under EMA review for the treatment of TSC. The Company has a deep pipeline of additional cannabinoid product candidates, in particular nabiximols, for which the Company is advancing multiple late-stage clinical programs in order to seek FDA approval in the treatment of spasticity associated with multiple sclerosis and spinal cord injury. The Company has additional cannabinoid product candidates in clinical trials for autism and schizophrenia.

Aphria

HEXO Corp

These cannabis stocks boast sizzling sales growth. But are they great picks for investors to buy now?

3 Cannabis Stocks With the Fastest-Growing Sales

GW Pharmaceuticals PLC (NASDAQ: GWPH) produces the only cannabis-derived drug approved by the Food and Drug Administration: Epidiolex, for the treatment of seizures in children.

Cramer: Epidiolex Maker GW Pharma Is Far From A 'Sketchy' Weed Business

Innovative Industrial Properties

Neptune Wellness Solutions Inc.

Although most cannabis stock earnings estimates are falling, these companies are bucking the trend.

3 Pot Stocks With Rising Profit Projections

"We're really at the beginning of this journey," GW Pharmaceuticals CEO Justin Gover tells CNBC's Jim Cramer.

GW Pharma CEO: More education needed on real health benefits of drugs derived from cannabis

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) reported second-quarter earnings and revenue Tuesday that blew past estimates, sending its shares solidly higher Wednesday.

GW Pharma Analysts Raise Estimates After CBD Drug Epidiolex Shows Strong Uptake

The company's fundamentals got a major boost from its star drug, Epidiolex.

GW Pharmaceuticals Q2 Results Crush Revenue Estimates; Stock Soars

Fast-growing CBD drug sales powered yet another tremendous quarter for the cannabis-focused biotech.

3 Things You'll Want to Know About GW Pharmaceuticals' Sizzling Q2 Results

GW Pharmaceuticals' (GWPH) CEO Justin Gover on Q2 2019 Results - Earnings Call Transcript

GW Pharmaceuticals stock rocketed late Tuesday after sales of cannabis medicine Epidiolex crushed analyst estimates at $68.4 million. Epidiolex is derived from the cannabis plant.

GW Pharma Stock Rockets As Cannabis Medicine Sales Crush Views

GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH), the British manufacturer of the CBD drug Epidiolex, said Tuesday that the medication posted net sales of $68.4 million during the quarter and $101.9 million in the first half of 2019.

GW Pharma Posts Second-Quarter Epidiolex Sales Of $68.4M

Aurora Cannabis

Canopy Growth

Cronos Group

Tilray Brands

Cannabis stocks bounced back on Friday, trading higher in sympathy with a big earnings beat and 35% gain from Aphria Inc (NYSE: APHA).

Cannabis Stocks Are The Latest Target Of Short Sellers

Admittedly, GWPH stock could go either way before earnings. The sector in general has suffered amid falling prices for dried cannabis.

GWPH Stock: Expect the Unexpected Coming Into Earnings

GW Pharmaceuticals (GWPH) is witnessing a solid new patient recruitment for Epidolex and a huge number of physicians are recommending the same in their prescriptions.

Can Patient Wins Aid GW Pharmaceuticals (GWPH) Q2 Earnings?

On GW Pharmaceuticals' (GWPH) second-quarter conference call, investor focus will be on the initial sales uptick of its newly launched anti-epileptic drug Epidiolex.

Can GW Pharmaceuticals (GWPH) Deliver a Beat in Q2 Earnings?

DexCom

Evolus

Here we discuss four medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.

4 Medical Product Stocks Set to Beat This Earnings Season

Curaleaf Holdings, Inc.

CVS Health

The U.S. Food and Drug Administration's harsh stance on cannabidiol should surprise no one.

The FDA Just Showed Its Hand on CBD -- Is It Time for Investors to Fold?

Green Thumb Industries Inc.

Trulieve Cannabis Corp.

These are the only cannabis stocks with a billion-dollar valuation.

The 13 Largest Marijuana Stocks in the World

GW Pharmaceuticals stock leapt higher Friday after European officials adopted a positive opinion of its CBD oil seizure treatment, a drug to be sold under the brand name Epidyolex.

This Biotech Stock Flew Higher On Likely CBD Oil Approval in Europe

GW Pharmaceuticals Plc  said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use had given a positive opinion about the marketing authorization of GW's oral cannibidiol drug, Epidyolex, as an adjunctive therapy for seizures associated with Lennox-Gastaut syndrome and Dravet syndrome. GW said it expects the European Commission to make a final decision on the marketing authorization in two months.

European Medicines Agency gives positive opinion on GW Pharma's cannibidiol drug

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) is inching closer to clearing another regulatory hurdle with respect to its cannabidiol drug Epidiolex, potentially opening up a market opportunity in Europe.

GW Pharma Receives EU Regulatory Agency Panel Backing For Epidiolex

GW Pharmaceuticals PLC (GWPH) closed the most recent trading day at $161.94, moving +0.32% from the previous trading session.

GW Pharmaceuticals PLC (GWPH) Gains But Lags Market: What You Should Know

Epidiolex sales figures will be key data when the results are published.

GW Pharma's Results Could Provide Further Stock Price Boost

Scotts Miracle-Gro

The recent legalization of marijuana in several states in the US has had many people eager to invest in the emerging sector.

Legal Cannabis Faces Competition from Black Market: 3 Stocks That Can Lead the Brigade

CannTrust Holdings

OrganiGram Holdings Inc.

Canadian cannabis companies have leapt onto U.S. stock markets, dazzling investors.

Mapping Out Canada's Cannabis Invasion Of The U.S.

Several economists and market researchers believe that the four  bills may pave the way for marijuana ETFs, which are likely to attract billions of dollars in investment.

News for GW Pharmaceuticals Stock (GWPH)